Gary M. Oosta holds a Ph.D. in Biophysics from Massachusetts Institute of Technology and a B.A. in Chemistry from E. Mich. Univ. Dr. Oosta has authored 28 technical publications and is an inventor on 77 patents worldwide. Dr. Oosta’s interest in Strategic Technology Forecasting was triggered early in his career by a senior manager at Agfa-Gevaert / Bayer. He applied and extended the lessons learned over a 25 year career in industrial research at Abbott Labs, Miles Labs/Bayer and in the US Army where he investigated various technology areas including medical diagnostics, thin-layer coating, bio-effects of electromagnetic radiation and blood coagulation and participated in multiple internal corporate ventures. More recently, Dr. Oosta has been consulting for large and small firms in the area of Strategic Technology Forecasting, a business process that leads to more informed, more targeted research program decisions. The visualizations developed by Dr. Oosta tell the story of research and technology developments in a business friendly way that can lead to insights that might otherwise have been overlooked.
Exosomes and Microvesicles: A Technology and Market Review
Thursday, 18 September 2014 at 17:45
Add to Calendar ▼2014-09-18 17:45:002014-09-18 18:45:00Europe/LondonExosomes and Microvesicles: A Technology and Market ReviewExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Exosomes, the “trash bag” of a cell, may also be a diagnostic or therapeutic gold mine. In this presentation we will explore research activity in exosomes or microvesicles using technology analytic methods to better understand technology developments in selected market segments. The process spotlights technology drivers and drags in exosome research. The technology analysis process begins by carefully forming a database of papers/abstracts from PubMed covering exosomes. Trends (from segments) in the database were discovered using well-chosen keywords, text clustering, adjacent word (adjective) discovery routines as well as web research and marketing research reports. The process is an objective method to survey the entire exosome field. Our analysis shows that the exosome space has shown dramatic growth for the last few years, and shows no signs of stopping. Exosome nomenclature is a nightmare that is just beginning to resolve itself. Our analysis of over 470 segments shows that the apoptosis and cancer are large - even dominant – segments, but that many other areas are well represented as well. High growth segments (drivers) and slow growth segments (drags) will be discussed. Some segments are connected to others as parts of a disease, a technology or as a tool used in an area. We highlight the connections among segments with a Hot Spot Map. Mapping results show some expected connections and some surprises. The analysis and mapping suggest that the exosome space is ripe for further growth. It is clear that commercial entities are interested, but that most research is still academic. Our analysis also hints that the area could benefit by collaborating with more “established” new areas such as cancer biomarkers.
Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonExosomes and Single Cell Analysis SummitExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-09-18 17:45:002014-09-18 18:45:00Europe/LondonExosomes and Microvesicles: A Technology and Market ReviewExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
